c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy
Open Access
- 20 April 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 84 (2), 129-134
- https://doi.org/10.1002/(sici)1097-0215(19990420)84:2<129::aid-ijc6>3.0.co;2-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Drug Resistance in OncologyPublished by Informa UK Limited ,1997
- P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancerBreast Cancer Research and Treatment, 1997
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piBritish Journal of Cancer, 1996
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapyCancer, 1996
- Changes in biological markers after primary chemotherapy for breast cancersInternational Journal of Cancer, 1995
- Preoperative chemotherapy in operable breast cancerThe Lancet, 1993
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapyYonsei Medical Journal, 1992
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 1988